

# Bio-Plex Pro Human SARS-CoV-2 N/RBD/S1/S2 4-Plex Panels

# High-Performance Multiplex SARS-CoV-2 Serology Assays for Antibody Response Profiling

ENABLED

IgA, IgG, and IgM antibodies against four SARS-CoV-2

Nucleocapsid

antigens:

**MAGNETIC** 

**SEPARATION** 

Receptor binding domain

Spike 1

Spike 2

- Acute Phase Response
- Cancer
- Cardiovascular Disease
- Cytokines, Chemokines, and Growth Factors
- Neurology
- Toxicology
- Infectious Disease
- Immunoglobulin Isotyping
- Serology Assays
- Signal Transduction



Researchers are interested in measuring antibodies specific to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to determine the exposure rates to the virus in a population, the humoral response to coronavirus disease 2019 (COVID-19) vaccines, and the immune response over time in patients with COVID-19 who have different levels of disease severity. The novelty of symptoms related to COVID-19 inspires a need for researchers to understand how long the humoral and cellular adaptive immune response lasts.

#### **New Challenges, New Solution**

These assays provide an efficient way for researchers to simultaneously profile isotype-specific antibody responses to four SARS-CoV-2 antigens: nucleocapsid, receptor binding domain (RBD), spike 1, and spike 2. These qualitative multiplexed immunoassays have been developed to support research validation and ensure high precision, specificity, and sensitivity.

A negative and a positive control are provided. Sample interpretation guidelines offer median fluorescence intensity (MFI) cutoff values to enable determination of which samples are positive for antibodies to a specific SARS-CoV-2 antigen. Representative cutoff values provided were based on 282 SARS-CoV-2-negative samples that were collected before December 2015. An isotype-specific positive control with recombinant antibodies specific to the SARS-CoV-2 antigens is included and can be used to compare MFI values across plates.

#### **Research Assay Features**

- Reduced turnaround time
- Reproducible results
- Specific and sensitive for SARS-CoV-2
- Flexible assay configurations
- Antigen-coupled beads and reagents for multispecies studies

#### **Supports Rigorous Assay Validation**

- Specificity (cross-reactivity)
- Inter- and intra-assay precision
- Correlation with COVID-19 and healthy serum and plasma samples



# **Bio-Plex SARS-CoV-2 Serology Assays Performance Characteristics**

#### Representative Clinical Specificity and Sensitivity

	Clinical Specificity, %*			Clinical Sensitivity, %**		
Viral Antigens	IgA n = 282	lgG n = 282	IgM n = 282	IgA n = 59	IgG n = 65	IgM n = 68
Nucleocapsid	100	99	94	93	100	82
RBD	98	96	95	98	100	97
S1	100	99	96	93	98	99
S2	100	95	94	95	100	94

n, number of samples run.

# Assay and Representative Performance Characteristics

Parameter	IgA	IgG	IgM
Reactive species	Human	Human	Human
Compatible sample matrices	Serum, plasma	Serum, plasma	Serum, plasma
Analytical specificity, % analyte cross-reactivity	<5	<5	<5
Intra-assay precision, %CV	<10	<10	<10
Inter-assay precision, %CV	<15	<15	<15

CV, coefficient of variation.

#### **Bio-Plex SARS-CoV-2 Serology Assays Cross-Reactivity Results**

#### **Cross-Reactivity Results**


			Negative		
Antibody Positive Sera	Number of Samples	Positive	IgA	IgG	IgM
CMV	3	0	3	3	3
EBV	3*	0	2	1	2
Hepatitis A	1	0	1	1	1
Hepatitis B	1	0	1	1	1
HIV	1	0	1	1	1
HTLV	1	0	1	1	1
Mumps	2	0	2	2	2
Influenza A	2	0	2	2	2
Influenza B	2	0	2	2	2
RSV	2	0	2	2	2
TOXO	1	0	1	1	1
WNV	1	0	1	1	1

<sup>\*</sup> One sample was tested for IgG and two samples were tested for IgA and IgM.

<sup>\*</sup> Clinical specificity was determined by testing 282 SARS-CoV-2-negative samples that were collected earlier than December 2015.


<sup>\*\*</sup> Clinical sensitivity was determined by samples from patients who previously had a SARS-CoV-2-positive PCR result.

# **IgA Antibody Profile of Healthy and Diseased Samples in COVID-19 Infection**




IgA antibody profile against four SARS-CoV-2 antigens. The diseased samples (n = 59) were obtained from donors who were SARS-CoV-2 positive. The healthy samples (n = 282) were collected from healthy donors prior to December 2015. Both serum and plasma samples were included in the study. Healthy ( ); diseased ( ).

# IgG Antibody Profile of Healthy and Diseased Samples in COVID-19 Infection



IgG antibody profile against four SARS-CoV-2 antigens. The diseased samples (n = 65) were obtained from donors who were SARS-CoV-2 positive. The healthy samples (n = 282) were collected from healthy donors prior to December 2015. Both serum and plasma samples were included in the study. Healthy ( ); diseased ( ).

# IgM Antibody Profile of Healthy and Diseased Samples in COVID-19 Infection



**IgM** antibody profile against four SARS-CoV-2 antigens. The diseased samples (n = 68) were obtained from donors who were SARS-CoV-2 positive. The healthy samples (n = 282) were collected from healthy donors prior to December 2015. Both serum and plasma samples were included in the study. Healthy ( ); diseased ( ).

#### **Ordering Information**

Catalog # Description

**Multiplex Assays** 

12014665 Bio-Plex Pro Human IgA SARS-CoV-2 N/RBD/S1/S2

4-Plex Panel, 1 x 96-well

12014634 Bio-Plex Pro Human IgG SARS-CoV-2 N/RBD/S1/S2

4-Plex Panel, 1 x 96-well

12014666 Bio-Plex Pro Human IgM SARS-CoV-2 N/RBD/S1/S2

**4-Plex Panel**, 1 x 96-wel

Singleplex Items

12014667 Bio-Plex Pro SARS-CoV-2 N/RBD/S1/S2 4-Plex

Coupled Beads

12014773 Bio-Plex Pro SARS-CoV-2 Nucleocapsid Coupled Beads 12015406 Bio-Plex Pro SARS-CoV-2 Receptor Binding Domain

Coupled Beads

Catalog #	Description
Singleplex Item	s (continued)
12014771	Bio-Plex Pro SARS-CoV-2 Spike 1 Coupled Beads
12014772	Bio-Plex Pro SARS-CoV-2 Spike 2 Coupled Beads
12014669	Bio-Plex Pro Human IgA Detection Antibody
12014775	Bio-Plex Pro Human IgA SARS-CoV-2 Positive and
	Negative Controls
12014668	Bio-Plex Pro Human IgG Detection Antibody
12014774	Bio-Plex Pro Human IgG SARS-CoV-2 Positive and
	Negative Controls
12014670	Bio-Plex Pro Human IgM Detection Antibody
12014776	Bio-Plex Pro Human IgM SARS-CoV-2 Positive and
	Negative Controls
12014777	Bio-Plex Pro Human Serology Reagent Kit

Visit bio-rad.com/SARS-CoV-2Serology for more information.

BIO-RAD and BIO-PLEX are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions. All trademarks used herein are the property of their respective owner.

For research use only. Not for use in diagnostic procedures.



Bio-Rad Laboratories, Inc.

Life Science Group Website bio-rad.com USA 1 800 424 6723 Australia 61 2 9914 2800 Austria 00 800 00 24 67 23 Belgium 00 800 00 24 67 23 Brazil 4003 0399 Canada 1 905 364 3435 China 86 21 6169 8500 Czech Republic 00 800 00 24 67 23 Denmark 00 800 00 24 67 23 Finland 00 800 00 24 67 23 France 00 800 00 24 67 23 Gramany 00 800 00 00 24 67 23 Hong 852 2789 3300 Hungary 00 800 00 00 24 67 23 India 91 124 4029300 Israel 0 3 9636050 Italy 00 800 00 24 67 23 Japan 81 3 6361 7000 Korea 82 2 3473 4460 Luxembourg 00 800 00 24 67 23 Mexico 52 555 488 7670

The Netherlands 00 800 00 24 67 23 New Zealand 64 9 415 2280 Norway 00 800 00 24 67 23 Poland 00 800 00 24 67 23 Portugal 00 800 00 24 67 23 Russian Federation 00 800 00 24 67 23 Singapore 65 6415 3188 South Africa 00 800 00 24 67 23 Spain 00 800 00 24 67 23 Sweden 00 800 00 24 67 23 Switzerland 00 800 00 24 67 23 Taiwan 886 2 2578 7189 Thailand 66 2 651 8311 United Arab Emirates 36 1 459 6150 United Kingdom 00 800 00 24 67 23

Bulletin 7430 Ver B US/EG 21-0437 0621 Sig 0121

